An aquaporin 4 antisense oligonucleotide loaded, brain targeted nanoparticulate system design

Pharmazie

Volumn 69, Issue 5, 2014, Pages 340-345

  Kozlu, S ^a   Caban, S ^a   Yerlikaya, F ^a   Fernandez Megia, E ^b   Novoa Carballal, R ^b   Riguera, R ^b   Yemisci, M ^a   Gursoy Ozdemir, Y ^a   Dalkara, T ^a   Couvreur, P ^c   Capan, Y ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AQUAPORIN 4; BIOTIN; CD71 ANTIGEN; CHITOSAN; MONOCLONAL ANTIBODY; NANOCARRIER; PHOSPHOROTHIOIC ACID; POLYMER; STREPTAVIDIN;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN TISSUE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; HYDROPHOBICITY; NANOENCAPSULATION; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; TRANSCYTOSIS; ZETA POTENTIAL;

AQUAPORIN 4; BRAIN; BRAIN EDEMA; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ELECTROCHEMISTRY; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 84900540166     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.3149     Document Type: Article

References (42)

1. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7: 41-53. (Pubitemid 41828930)
2. Agrawal S, Iyer RP (1997) Perspectives in antisense therapeutics. Pharmacol Ther 76: 151-60. (Pubitemid 28078568)
3. Agre P (1997) Molecular physiology of water transport: aquaporin nomenclature workshop. Mammalian aquaporins. Biol Cell 89: 255-257.
4. Agre P, King LS, Yasui M, Guggino WB, Ottersen OP, Fujiyoshi Y, Engel A, Nielsen S (2002) Aquaporin water channels-from atomic structure to clinical medicine. J Physiol 542: 3-16. (Pubitemid 35190266)
5. Agre P, Kozono D (2003) Aquaporin water channels: molecular mechanisms for human diseases. FEBS Lett 555: 72-78. (Pubitemid 37431100)
6. Aktas Y, Yemisci M, Andrieux K, Gursoy RN, Alonso MJ, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Riguera R, Sargon MF, Celik HH, Demir AS, Hincal AA, Dalkara T, Capan Y, Couvreur P (2005) Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 16: 1503-1511. (Pubitemid 41681517)
7. Amiry-Moghaddam M, Ottersen OP (2003) The molecular basis of water transport in the brain. Nat Rev Neurosci 4: 991-1001. (Pubitemid 37486675)
8. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ (1997) Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 14: 1431-1436. (Pubitemid 27481075)
9. Campbell JM, Bacon TA, Wickstrom E (1990) Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Methods 20: 259-267. (Pubitemid 20111713)
10. Crooke ST (2000) Progress in antisense technology: the end of the beginning. Methods Enzymol 313: 3-45.
11. Dias N, Stein CA (2002a) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1: 347-355.
12. Dias N, Stein CA (2002b) Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 54: 263-269. (Pubitemid 35341825)
13. Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Riguera R (2007) Conjugation of bioactive ligands to PEG-grafted chitosan at the distal end of PEG. Biomacromolecules 8: 833-842. (Pubitemid 46488462)
14. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P (2005) Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 298: 274-292. (Pubitemid 40910731)
15. Haj-Yasein NN, Vindedal GF, Eilert-Olsen M, Gundersen GA, Skare O, Laake P, Klungland A, Thoren AE, Burkhardt JM, Ottersen OP, Nagelhus EA (2015) Glial-conditional deletion of aquaporin-4 (Aqp4) reduces blood-brain water uptake and confers barrier function on perivascular astrocyte endfeet. Proc Natl Acad Sci U S A 108: 17815-17820.
16. Jason TL, Koropatnick J, Berg RW (2004) Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 201: 66-83. (Pubitemid 39446327)
17. Jung JS, Bhat RV, Preston GM, Guggino WB, Baraban JM, Agre P (1994) Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci U S A 91: 13052-13056.
18. Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, Caban S, Vural A, Pinarbasli O, Capan Y, Fernandez-Megia E, Novoa-Carballal R, Riguera R, Andrieux K, Couvreur P, Dalkara T (2009) A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci 29: 13761-13769.
19. Lee LK, Roth CM (2003) Antisense technology in molecular and cellular bioengineering. Curr Opin Biotechnol 14: 505-511. (Pubitemid 37298035)
20. Lochmann D, Jauk E, Zimmer A (2004) Drug delivery of oligonucleotides by peptides. Eur J Pharm Biopharm 58: 237-251. (Pubitemid 39037232)
21. Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, Bollen AW, Chan P, Verkman AS (2000) Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 6: 159-163. (Pubitemid 30082359)
22. Migliati E, Meurice N, DuBois P, Fang JS, Somasekharan S, Beckett E, Flynn G, Yool AJ (2009) Inhibition of aquaporin-1 and aquaporin-4 water permeability by a derivative of the loop diuretic bumetanide acting at an internal pore-occluding binding site. Mol Pharmacol 76: 105-112.
23. Misra A, Ganesh S, Shahiwala A, Shah SP (2003) Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 6: 252-273. (Pubitemid 37207232)
24. Monia BP, Johnston JF, Sasmor H, Cummins LL (1996) Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J Biol Chem 271: 14533-14540. (Pubitemid 26190357)
25. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP (1997) Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 17: 171-180. (Pubitemid 27008860)
26. Novoa-Carballal R, Riguera R, Fernandez-Megia E (2013) Disclosing an NMR-invisible fraction in chitosan and PEGylated copolymers and its role on the determination of degrees of substitution. Mol Pharm 10:3225-3231.
27. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM (2002) Synthesis of pegylated immunonanoparticles. Pharm Res 19: 1137-1143. (Pubitemid 34984997)
28. Papadopoulos MC, Verkman AS (2007) Aquaporin-4 and brain edema. Pediatr Nephrol 22: 778-784. (Pubitemid 46629610)
29. Pardridge WM (2002) Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv Exp Med Biol 513: 397-430.
30. Pardridge WM (2003) Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3: 90-105, 51.
31. Prabaharan M (2008) Review paper: chitosan derivatives as promising materials for controlled drug delivery. J Biomater Appl 23: 5-36.
32. Ribeiro Mde C, Hirt L, Bogousslavsky J, Regli L, Badaut J (2006) Time course of aquaporin expression after transient focal cerebral ischemia in mice. J Neurosci Res 83: 1231-40. (Pubitemid 43668006)
33. Royer GP, Anantharmaiah GM (1979) Peptide-synthesis in water and the use of immobilized carboxypeptidase-Y for deprotection. J Am. Chem. Soc. 101: 3394-3396.
34. Saadoun S, Papadopoulos MC, Davies DC, Krishna S, Bell BA (2002) Aquaporin-4 expression is increased in oedematous human brain tumours. J Neurol Neurosurg Psychiatry 72: 262-265.
35. Tait MJ, Saadoun S, Bell BA, Papadopoulos MC (2008) Water movements in the brain: role of aquaporins. Trends Neurosci 31: 37-43.
36. Torchilin VP, Levchenko TS, Whiteman KR, Yaroslavov AA, Tsatsakis AM, Rizos AK, Michailova EV, Shtilman MI (2001) Amphiphilic poly-N- vinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials 22: 3035-3044. (Pubitemid 32768711)
37. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA (2008) Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 5: 155-174. (Pubitemid 351308309)
38. Ulbrich K, Hekmatara T, Herbert E, Kreuter J (2009) Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 71: 251-256.
39. Verkman AS (2002) Aquaporin water channels and endothelial cell function. J Anat 200: 617-627.
40. Verkman AS, Binder DK, Bloch O, Auguste K, Papadopoulos MC (2006) Three distinct roles of aquaporin-4 in brain function revealed by knockout mice. Biochim Biophys Acta 1758: 1085-1093. (Pubitemid 44376750)
41. Yang B, Verkman AS (1997) Water and glycerol permeabilities of aquaporins 1-5 and MIP determined quantitatively by expression of epitope-tagged constructs in Xenopus oocytes. J Biol Chem 272: 16140-16146. (Pubitemid 27276428)
42. Yool AJ, Brown EA, Flynn GA (2010) Roles for novel pharmacological blockers of aquaporins in the treatment of brain oedema and cancer. Clin Exp Pharmacol Physiol 37: 403-409.